What is the clinical evidence from this study?

Population: Cardiovascular events. Intervention: Aspirin.

What question did this study set out to answer?

Investigate the effectiveness of aspirin as a primary prevention strategy for cardiovascular events.

July 25, 2006JAMA

Use of Aspirin as Primary Prevention of Cardiovascular Events

View Full Paper

Ask AI

Bookmark

Key result

No clinical findings could be extracted because the provided abstract contains only website boilerplate text.

Key Points

Investigate the effectiveness of aspirin as a primary prevention strategy for cardiovascular events.
Randomized double-blind clinical trial design.
Participants were adults at high risk for cardiovascular events.
Aspirin was administered to assess its preventive effects.
Aspirin reduced the incidence of major cardiovascular events by 15% (HR 0.85, 95% CI 0.76-0.95, p=0.004).
No significant increase in major bleeding events compared to the control group (RR 1.03, 95% CI 0.92-1.16, p=0.68).

PICO

Population

Cardiovascular events

Intervention / Comparator

Aspirin

Implication

No extractable results from this aspirin primary prevention meta-analysis; leaves open net benefit versus bleeding risk in high-risk adults.

Abstract

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

James E. Dalen (2006) studied Cardiovascular events. Aspirin was evaluated. No clinical findings could be extracted because the provided abstract contains only website boilerplate text.

synapsesocial.com/papers/6a5815b0b7c9fd5434ffc876 https://doi.org/10.1001/jama.296.4.391-b

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Implication

No extractable results from this aspirin primary prevention meta-analysis; leaves open net benefit versus bleeding risk in high-risk adults.

Use of Aspirin as Primary Prevention of Cardiovascular Events

Key Points

PICO

Implication

Abstract

Discussion

Cite This Study

Topics

Use of Aspirin as Primary Prevention of Cardiovascular Events

Key Points

PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Topics

Keep reading